Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claims 1-97 canceled.

Claim 98 (currently amended): A nucleic acid ~~sequence~~ encoding a chimeric protein, the chimeric protein comprising:

a first peptidyl fragment;

a second peptidyl fragment comprising a human insulin precursor; ~~an amino acid sequence which comprises at least two cysteine residues which form at least one cysteine bridge in a bioactive conformation of the second peptidyl fragment~~; and

at least one cleavable peptidyl fragment linking the first and second peptidyl fragments;

the first peptidyl fragment having sufficient amino acid sequence homology to at least a first 20 N-terminal amino acids of human growth hormone (hGH) protein that the first peptidyl fragment mediates formation of the bioactive conformation of the second peptidyl fragment.

Claim 99 (currently amended): The [[A]] nucleic acid ~~sequence~~ according to claim 98, wherein the C-terminus of the first peptidyl fragment is adjacent the N-terminus of the second peptidyl fragment.

Claim 100 (currently amended): The [[A]] nucleic acid ~~sequence~~ according to claim 98, wherein the first peptidyl fragment is capable of being bound by an anti-hGH antibody.

Claim 101 (currently amended): The [[A]] nucleic acid ~~sequence~~ according to claim 98, wherein the first peptidyl fragment comprises the amino acid sequence of SEQ ID NO:1.

Claim 102 (currently amended): The [[A]] nucleic acid ~~sequence~~ according to claim 98, wherein the first peptidyl fragment comprises the amino acid sequence of SEQ ID NO:2.

Claim 103 (currently amended): The [[A]] nucleic acid ~~sequence~~ according to claim 98, wherein the first peptidyl fragment comprises the amino acid sequence of SEQ ID NO:3.

Claim 104 (currently amended): The [[A]] nucleic acid ~~sequence~~ according to claim 98, wherein the first peptidyl fragment is between 20 and 200 residues in length.

Claims 105-108 (canceled).

Claim 109 (currently amended): The [[A]] nucleic acid ~~sequence~~ according to claim 98, wherein the second peptidyl fragment comprises the amino acid sequence of SEQ ID NO:4.

Claim 110 (currently amended): The [[A]] nucleic acid ~~sequence~~ according to claim 98, wherein the second peptidyl fragment comprises the amino acid sequence of SEQ ID NO:5.

Claim 111 (currently amended): The [[A]] nucleic acid ~~sequence~~ according to claim 98, wherein the second peptidyl fragment comprises A chain and B chain amino acid sequences of human insulin separated by an amino acid sequence between 1 and 34 residues in length.

Claims 112 -113 (canceled).

Claim 114 (currently amended): The [[A]] nucleic acid ~~sequence~~ according to claim 98, wherein the cleavable peptidyl fragment is an Arg or Lys residue.

Claim 115 (currently amended): The [[A]] nucleic acid ~~sequence~~ according to claim 98, wherein the cleavable peptidyl fragment is at least 2 amino acids in length where the C-terminal amino acid residue is selected from the group consisting of Arg and Lys.

Claim 116 (currently amended): The [[A]] nucleic acid ~~sequence~~ according to claim 98, wherein the protein comprises the amino acid sequence of SEQ ID NO:6.

Claim 117 (currently amended): The [[A]] nucleic acid ~~sequence~~ according to claim 98, wherein the protein comprises the amino acid sequence of SEQ ID NO:7.

Claim 118 (currently amended): A cell comprising the nucleic acid of claim 98, wherein the cell expresses the chimeric protein. ~~capable of expressing a recombinant protein which comprises:~~

~~a first peptidyl fragment;~~

~~a second peptidyl fragment comprising an amino acid sequence which comprises at least two cysteine residues which form at least one cysteine bridge in a bioactive conformation of the second peptidyl fragment; and~~

~~at least one cleavable peptidyl fragment linking the first and second peptidyl fragments;~~

~~the first peptidyl fragment having sufficient homology to at least a first 20 N-terminal amino acids of human growth hormone (hGH) protein that the first peptidyl fragment mediates formation of the bioactive conformation of the second peptidyl fragment.~~

Claim 119 (currently amended): The [[A]] cell according to claim 118 wherein the C-terminus of the first peptidyl fragment is adjacent the N-terminus of the second peptidyl fragment.

Claim 120 (currently amended): The [[A]] cell according to claim 118 wherein the first peptidyl fragment is capable of being bound by an anti-hGH antibody.

Claim 121 (currently amended): The [[A]] cell according to claim 118 wherein the first peptidyl fragment comprises the amino acid sequence of SEQ ID NO:1.

Claim 122 (currently amended): The [[A]] cell according to claim 118 wherein the first peptidyl fragment comprises the amino acid sequence of SEQ ID NO:2.

Claim 123 (currently amended): The [[A]] cell according to claim 118 wherein the first peptidyl fragment comprises the amino acid sequence of SEQ ID NO:3.

Claim 124 (currently amended): The [[A]] cell according to claim 118 wherein the first peptidyl fragment is between 20 and 200 residues in length.

Claims 125 - 128 (canceled).

Claim 129 (currently amended): The [[A]] cell according to claim 118 wherein the second peptidyl fragment comprises the amino acid sequence of SEQ ID NO:4.

Claim 130 (currently amended): The [[A]] cell according to claim 118 wherein the second peptidyl fragment comprises the amino acid sequence of SEQ ID NO:5.

Claim 131 (currently amended): The [[A]] cell according to claim 118 wherein the second peptidyl fragment comprises A chain and B chain amino acid sequences of human insulin separated by an amino acid sequence between 1 and 34 residues in length.

Claims 132 - 133 (canceled).

Claim 134 (currently amended): The [[A]] cell according to claim 118 wherein the cleavable peptidyl fragment is an Arg or Lys residue.

Claim 135 (currently amended): The [[A]] cell according to claim 118 wherein the cleavable peptidyl fragment is at least 2 amino acids in length where the C-terminal amino acid residue is selected from the group consisting of Arg and Lys.

Claim 136 (currently amended): The [[A]] cell according to claim 118 wherein the protein comprises the amino acid sequence of SEQ ID No:6.

Claim 137 (currently amended): The [[A]] cell according to claim 118 wherein the protein comprises the amino acid sequence of SEQ ID No:7.

Claim 138 (new): The nucleic acid according to claim 98, wherein the first peptidyl fragment is from 20 amino acids in length to 92 amino acids in length.

Claim 139 (new): The nucleic acid according to claim 98, wherein the first peptidyl fragment is between 20 and 49 residues in length.

Claim 140 (new): The nucleic acid of claim 98, wherein the first peptidyl sequence comprises a sequence identical to an N-terminal amino acid sequence of SEQ ID NO: 2 of the same length as the first peptidyl fragment or having an amino acid sequence which differs by one or two residues from the N-terminal sequence of SEQ ID NO:2 of the same length.

Claim 141 (new): The cell of claim 118, wherein the cell is a bacterial cell.

Claim 142 (new): The cell of claim 118, wherein the cell is a mammalian cell.

Claim 143(new): The cell of claim 118, wherein the first peptidyl fragment is between 20 and 49 residues in length.

Claim 144 (new): The cell of claim 118, wherein the first peptidyl sequence comprises a sequence identical to an N-terminal amino acid sequence of SEQ ID NO: 2 of the same length as the first peptidyl fragment or having an amino acid sequence which differs by one or two residues from the N-terminal sequence of SEQ ID NO:2 of the same length. --